Reinhard Kandera
Director of Finance/CFO presso HOOKIPA PHARMA INC.
Patrimonio netto: 30 682 $ in data 31/03/2024
Profilo
Reinhard Kandera is currently the Secretary & Director at Intercell USA, Inc., the Managing Director at Elatos GmbH, a Director at Vaccines Holdings Sweden AB, and the Chief Financial Officer & Director at HOOKIPA Pharma, Inc. He previously held positions as the Secretary & Director at Valneva Scotland Ltd., the Managing Director at VALNEVA Austria GmbH, the Chief Financial Officer & Head-Investor Relations at Intercell AG, and the Chief Financial Officer at Valneva SE.
Dr. Kandera obtained a doctorate degree from Vienna University of Economics & Business and a graduate degree from the University of Vienna.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
HOOKIPA PHARMA, INC.
0.05% | 15/04/2024 | 43 092 ( 0.05% ) | 30 682 $ | 31/03/2024 |
Posizioni attive di Reinhard Kandera
Società | Posizione | Inizio |
---|---|---|
IOMAI CORPORATION | Director/Board Member | - |
HOOKIPA PHARMA INC. | Director of Finance/CFO | 01/04/2017 |
Elatos GmbH | Corporate Officer/Principal | 01/12/2013 |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Director/Board Member | - |
Precedenti posizioni note di Reinhard Kandera
Società | Posizione | Fine |
---|---|---|
VALNEVA | Director of Finance/CFO | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Director of Finance/CFO | 28/05/2013 |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Corporate Officer/Principal | - |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Director/Board Member | - |
Formazione di Reinhard Kandera
Vienna University of Economics & Business | Doctorate Degree |
University of Vienna | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
VALNEVA | Health Technology |
HOOKIPA PHARMA INC. | Health Technology |
Aziende private | 6 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Health Technology |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
Elatos GmbH | |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
- Borsa valori
- Insiders
- Reinhard Kandera